Prevention of deep venous thrombosis after hip arthroplasty with aspirin

doi:10.3877/cma.j.issn.1674-134X.2019.05.002

Abstract

Abstract:

Objective

To evaluate the efficacy and safety of aspirin as a prophylaxis agent against venous thromboembolism following hip arthroplasty.

Methods

According to inclusion (older than 60 years) and exclusion criteria (blood coagulation disurbance), 124 cases of hip arthroplasty were recruited prospectively and divided into four groups by random number table as control group, aspirin group, sequential therapy group and combined therapy group. Each group contained 31 cases. The rates of deep venous thrombosis, bleeding risk and fee of antithrombotic agent were compared among groups five weeks postoperatively. Analysis of variance (ANOVA) was used to measurement data, and chi-square test was used to enumeration data.

Results

The total rate of deep venous thrombosis was 3.2% and there wase no significant difference among four groups and between each two groups (χ²=2.067, P>0.05). No serious bleeding affair happened. The cost of antithrombotic agent of the aspirin group was significantly lower than other groups(t=16.472, P<0.01).

Conclusion

Aspirin is effective and safe enough to prevent deep venous thrombosis following hip arthroplasty.

Key words: Aspirin, Arthroplasty, replacement, hip, Venous thrombosis, Anticoagulants

Jiansheng Yang, Wanning Guan, Zili Deng, Chaofu Li, Zhuopeng Wu. Prevention of deep venous thrombosis after hip arthroplasty with aspirin[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2019, 13(05): 526-529.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgjwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-134X.2019.05.002

https://zhgjwkzz.cma-cmc.com.cn/EN/Y2019/V13/I05/526

Figures/Tables 2

References 20

[1]	赵志刚，谢林，丁凡，等．利伐沙班预防关节置换术后下肢深静脉血栓的临床前瞻性对照研究[J]．中国矫形外科杂志，2016，24(07)：619-622.
[2]	熊涛，李秀山．利伐沙班预防骨科术后深静脉血栓及其对血液流变学的影响研究[J]．中华骨与关节外科杂志，2018，11(11)：846-848＋857.
[3]	Ishida K, Shibanuma N, Kodato K, et al. A prospective randomized comparative study to determine appropriate edoxaban administration period, to prevent deep vein thromboembolism in patients with total knee arthroplasty[J]. J Orthop Sci，2018，23(6)：1005-1010.
[4]	Nam D, Nunley RM, Johnson SR, et al. Thromboembolism prophylaxis in hip arthroplasty：routine and high risk patients[J]. J Arthroplasty，2015，30(12)：2299-303.
[5]	Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest, 2012, 141: 278-325.
[6]	中华医学会骨科学分会. 中国骨科大手术静脉血栓栓塞症预防指南[J]. 中华骨科杂志，2016, 36：65-69.
[7]	Chu JN, Maselli J, Auerbach AD, et al. The risk of venous thromboembolism with aspirin compared to anticoagulants after hip and knee arthroplasty[J]．Thrombosis research，2017，155：65-71.
[8]	Becattini C, Agnelli G. Aspirin for prevention and treatment of venous thromboembolism[J]. Blood Rev, 2014, 28 (1): 103-108.
[9]	Semeraro F, Ammollo CT, Morrissey JH, et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4[J]. Blood, 2011, 118：1952-1961.
[10]	Undas A, Undas R, Musial J, et al. A low dose of aspirin (75 mg/day) lowers thrombin generation to a similar extent as a high dose of aspirin (300 mg/day)[J]. Blood Coagul Fibrinolysis, 2000，11：231-234.
[11]	Drescher FS, Sirovich BE, Lee A, et al. Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: a systematic review and meta-analysis[J]. J Hosp Med，2014，9(9)：579-85.
[12]	Tan TL, Foltz C, Huang R, et al. Potent anticoagulation does not reduce venous thromboembolism in high-risk patients[J]. J Bone Joint Surg Am，2019，101(7)：589-599.
[13]	Nadi S, Vreugdenburg TD, Atukorale Y, et al. Safety and effectiveness of aspirin and enoxaparin for venous thromboembolism prophylaxis after total hip and knee arthroplasty: a systematic review[J]. 2019，15. doi: 10.1111/ans.15122.
[14]	An VV, Phan K, Levy YD, et al. Aspirin as thromboprophylaxis in hip and knee arthroplasty: a systematic review and meta-analysis[J]. J Arthroplasty, 31(11)：2608-2616.
[15]	Woon CYL, Shah RR, Pardi BM, et al. Aspirin alone is not enough to prevent deep venous thrombosis after total joint arthroplasty[J]．Orthopedics，2019，42(1)：48-55.
[16]	Anderson DR, Dunbar MJ, Bohm ER, et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial[J]. Ann Intern Med, 2013，158(11)：800-806.
[17]	Anderson DR, Dunbar M, Murnaghan J, et al. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty[J]. N Engl J Med, 2018，378(8)：699-707.
[18]	Schaefer JK, Li Y, Gu X, et al. Association of adding aspirin to warfarin therapy without an apparent indication with bleeding and other adverse events[J]. JAMA Intern Med, 2019, 4. doi: 10.1001/jamainternmed.2018.7816.
[19]	Hood BR, Cowen ME, Zheng HT, et al. Association of aspirin with prevention of venous thromboembolism in patients after total knee arthroplasty compared with other anticoagulants: a noninferiority analysis[J]. AMA Surg, 2018, 17. doi: 10.1001/jamasurg.2018.3858.
[20]	Parvizi J, Huang R, Restrepo C, et al. Low-dose aspirin is effective chemoprophylaxis against clinically important venous thromboembolism following total joint arthroplasty: a preliminary analysis[J]. J Bone Joint Surg Am，2017，99(2)：91-98.

分组	例数	年龄[岁，(±s)]	女性(例)	Caprini评分(±s)	BMI[kg/m²，(±s)]	全髋置换(例)
对照组	31	66.9±2.2	14	7.1±0.1	24.2±1.6	27
阿司匹林组	31	67.8 ±2.4	15	7.2±0.1	25.5±1.6	26
序贯治疗组	31	68.1±2.1	14	7.2±0.1	25.9±1.8	26
联合预防组	31	67.5±2.4	16	7.1±0.1	25.4±1.3	28
统计值	?	t＝1.684	χ²＝1.232	t＝0.844	t＝1.876	χ²＝0.579
P值	?	>0.05	>0.05	>0.05	>0.05	>0.05

分组	例数	年龄[岁，(±s)]	女性(例)	Caprini评分(±s)	BMI[kg/m²，(±s)]	全髋置换(例)
对照组	31	66.9±2.2	14	7.1±0.1	24.2±1.6	27
阿司匹林组	31	67.8 ±2.4	15	7.2±0.1	25.5±1.6	26
序贯治疗组	31	68.1±2.1	14	7.2±0.1	25.9±1.8	26
联合预防组	31	67.5±2.4	16	7.1±0.1	25.4±1.3	28
统计值	?	t＝1.684	χ²＝1.232	t＝0.844	t＝1.876	χ²＝0.579
P值	?	>0.05	>0.05	>0.05	>0.05	>0.05

分组	例数	静脉血栓总例数	腘静脉以上血栓例数
对照组	31	3	1
阿司匹林组	31	4	1
序贯治疗组	31	4	2
联合预防组	31	5	0
χ²值	?	0.574	2.067
P值	?	>0.05	>0.05^*

分组	例数	静脉血栓总例数	腘静脉以上血栓例数
对照组	31	3	1
阿司匹林组	31	4	1
序贯治疗组	31	4	2
联合预防组	31	5	0
χ²值	?	0.574	2.067
P值	?	>0.05	>0.05^*

Please choose a citation manager

Content to export